Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: My enemy's drug failure is not my drug's success

This article was originally published in Scrip

Executive Summary

In life sciences, big share price movements occur in response to merger and acquisition (M&A) activity, clinical trial results and regulatory events. Actual, rather than rumoured M&A is the panacea for many investors but some companies have played up to this by appearing to spend more effort stoking rumours of their impending acquisition than developing their drugs. Such is the case with Achillion Pharmaceuticals, whose cry of acquisition wolf after each of its hepatitis C virus (HCV) antiviral competitors is acquired has been accompanied by a share price rise and an inevitable fundraising by the company. It is illogical for investors to believe that any and all companies developing HCV antivirals will be acquired. Those that have been repeatedly passed over as competitors with better and more advanced products are snapped up seem to be unlikely M&A candidates, but when they shout loud enough, investors behave as if this is a maximum sum game.

You may also be interested in...

Stockwatch: Details Differ Between Pfizer And AstraZeneca's Second-Quarter Earnings Reports

Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.

Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche

Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.

Stockwatch: The Not-As-Bad-As-Expected Opera Of Johnson & Johnson’s Q2 Earnings

With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts